

Effect of a novel penetration enhancer on the unequal permeation of two antifungal agents

¹M. J. Traynor*, ³R.B. Turner, ³C.R.G. Evans, ²R.H. Khengar, ²S. A. Jones, ^{1,3}M.B. Brown,

¹*School of Pharmacy, University of Hertfordshire, College Lane, Hatfield, Herts AL10 9AB*

²*Pharmaceutical Science Research Division, Franklin-Wilkins Building, King's College London, 150 Stamford Street, London SE1 9NH, UK*

³*MedPharm Ltd, Unit 3 / Chancellor Court, 50 Occam Road, Surrey Research Park, Guildford, GU2 7YN*

**Corresponding author*

Matt Traynor

School of Pharmacy

University of Hertfordshire

Hatfield

AL10 9AB

UK

e-mail: m.j.traynor@herts.ac.uk

phone 01707 284383

ABSTRACT

Objectives: The aim of this study was to demonstrate the effect of a novel permeation enhancer system using two existing marketed nail lacquers and the delivery of terbinafine through human nail samples *in vitro*.

Methods: Initially a modified Franz cell was used, where sections of human nail serve as the barrier through which drug penetrates into an agar filled chamber infected with dermatophytes. A second study was performed using a novel infected nail model where dermatophytes are incubated with and grow into human nail and ATP levels are used as biological marker for antimicrobial activity.

Key Findings: The novel permeation enhancing system, increased the permeation of both existing drugs formulated in nail lacquers and terbinafine through human nail sections mounted in modified Franz cell. Furthermore the ATP assay confirmed that the system also enhanced the permeation of terbinafine through infected cadaver nail resulting in a decrease in ATP levels equivalent to those of uninfected negative control samples.

Conclusions: This study has clearly demonstrated that the use of a novel permeation enhancing system, which fundamentally alters the chemical structure of the nail not only enhances the efficacy of the existing topical formulations but enables the delivery and efficacy of terbinafine when applied ungually. Such a topically applied system has the possibility of overcoming the systemic side effects when terbinafine is delivered orally.

Key Words: nail, permeation enhancer, ungual, onychomycosis, terbinafine

INTRODUCTION

Onychomycosis is a fungal infection of the nail that accounts for approximately 50% of all nail disorders and affects toenails substantially more than fingernails [1]. The prevalence of onychomycosis has been estimated at around 5% in Western countries and has continued to increase in recent decades [2-8]. While onychomycosis may be caused by dermatophytes, yeasts or moulds it is accepted that the former are by far the predominant pathogens and probably account for more than 85% of all cases of fungal nail infections. Of the dermatophytes the most common cause of onychomycosis is *Trichophyton rubrum* (*T.rubrum*) [5, 9]. Causative moulds include *Scopulariopsis brevicaulis* and *Scytalidium dimidiatum*.

Distal and lateral subungual onychomycosis (DLSO) is the commonest type of onychomycosis. Infection is initially a disease of the hyponychium, resulting in hyperkeratosis of the distal nail bed. It generally begins at the lateral edge of the nail rather than the central portion and spreads progressively proximally down the nail bed producing hyperkeratosis and thus onycholysis. Ultimately the underside of the nail is involved which results in thickening of the nail. The nail may become friable and crumbles away. Sometimes the fungus proliferates in the space between the nail plate and nail bed (known as a dermatophytoma) [10] and is often the cause of treatment failure [3].

It is important to treat onychomycosis, as it is an infection that does not resolve spontaneously. The infection may worsen, spread to other uninfected locations (other nails or to the surrounding skin) or infect other patients. Infections of the fingernails may be cosmetically unacceptable. Infections of the toenail can greatly affect the quality of life of patients and cause pain and morbidity [9].

Treatment for onychomycosis may be topical or oral. There have been four main oral therapies available for the treatment of onychomycosis. These are griseofulvin (Grisovin[®], Glaxo Wellcome) ketoconazole (Nizoral[®], Janssen-Cilag), itraconazole (Sporanox[®], Janssen-Cilag) and terbinafine (Lamisil[®], Novartis). Griseofulvin has been available since the 1950's and due to its fungistatic activity against dermatophytes requires long treatment periods (9-12 months for toenail infections) with low cure rates and high relapse rates [11, 12]. Ketoconazole was the first imidazole introduced for the treatment of onychomycosis in the 1980's. However, due to hepatotoxicity its use is now restricted to fingernail infections that have failed to respond to other therapies. The newer antifungals, itraconazole and terbinafine, are highly effective in the treatment of onychomycosis with mycological cure rates of 70-80% and treatment periods of 12-16 weeks [12-14]. The main disadvantages of systemic oral

treatments is that they can cause systemic toxicity and may also cause significant drug interactions so it is important to review and document concomitant medications prior to commencing treatment [13, 15].

Topical therapies include amorolfine (Loceryl[®], Galderma) and ciclopirox (Penlac[®], Dermik) [16-20]. Probably as a result of the poor drug penetration from these products through the nail, treatment times are long (12 months for toenail infections) and cure rates are low [3, 12, 21] and alternative drugs and formulations to improve delivery are being sought.

Permeation of drugs through the skin has been extensively documented in the last 60 years [22-29], while permeation of drugs through the nail remains a relatively undocumented area. In comparison to the thin *Stratum corneum*, the much thicker nail plate means a much longer diffusional pathway for drug delivery. In addition, in contrast to the elastic and pliable *Stratum corneum*, the nail plate is dense and hard. However, when the thickness difference is taken into consideration, the water permeation rate of the nail is ca. 10 times higher than that of the *Stratum corneum*. As such it would be expected that the permeation characteristics of the nail are very different from the *Stratum corneum*, which is supported by the current literature [3, 30].

The physical and chemical differences between the nail and *Stratum corneum*, are probably the reasons for the lack of efficacy of topical nail antifungal formulations presently on the market as they have been developed based on knowledge of the barrier properties of the skin. Thus, when designing topical formulations for perungual drug absorption it is essential to consider the physicochemical properties of the drug molecule (e.g. size, shape, charge log P etc), the formulation characteristics (e.g. vehicle, pH drug concentration), possible penetration enhancers, as well as any possible interactions between the drug and keratin. Monti *et al* showed that incorporation of the water soluble film forming agent hydroxypropyl chitosan (HPCH) in a nail lacquer resulted in a decreased lag time in the uptake of ciclopirox compared to Penlac[®]. The authors suggested that this was likely to be due to the adhesive properties of HPCH when in contact with biological membranes, and the formation of hydrogen bonds between the hydroxypropyl groups on the HPCH and the keratin resulting in intimate contact between the vehicle and the keratin matrix thus enhancing transfer of ciclopirox from the vehicle in to the nail matrix [31]. Malhotra and Zatz investigated a wide range of possible nail permeation enhancers using tritiated water as a probe. They postulated that any potential permeation enhancer would induce changes in the primary or higher order structure of keratin thus making the

nail more permeable. Molhotra and Zatz tested a wide range of compounds including mercaptan compounds, sulfites and bisulfites, keratolytic agents and surfactants. They concluded that the most effective enhancing agents produced irreversible changes to the keratin matrix compromising its barrier function, whereas those compounds that were not as effective produced minor reversible changes to the barrier function that was quickly restored [32]. A range of non-chemical physical enhancement techniques, including abrasion or etching of the nail surface, ultrasound and microproration have also been investigated by a range of authors and are comprehensively reviewed elsewhere [33].

Described in this paper is a novel penetration enhancer consisting of sequential application of a reducing agent and an oxidising agent used as a pre-treatment prior to application of a pharmaceutically active agent. Khengar *et al.*, previously tested a range of reducing and oxidising agents using a nail swelling model to predict the enhancing effect of such agents [34]. The authors identified thioglycolic acid and urea hydrogen peroxide as being the reducing and oxidising agents which produce the greatest level of enhancement of those tested. Brown *et al.* subsequently tested the enhancing potential of these agents alone and in combination with each other and discovered that treatment of the nail with thioglycolic acid followed by urea hydrogen peroxide had the greatest penetration enhancing effect on a range of model permeants [35]. This pre-treatment (thioglycolic acid followed by hydrogen peroxide) is not a product on its own, it has no therapeutic effect and contains no active ingredients, it is a penetration enhancer that has the capability to alter the barrier properties of the nail such that it becomes more permeable to antifungal agents such as ciclopirox, amorolfine and terbinafine.

This study aims to demonstrate the effect of a novel penetration enhancing system on the permeation of two drugs, amorolfine and ciclopirox presented in two marketed nail lacquers and terbinafine applied in a spray system developed in house.

MATERIALS AND METHODS

TA and urea hydrogen peroxide addition compound (urea H₂O₂) were purchased from Sigma-Aldrich (Dorset, UK). Human nail clippings were donated from healthy volunteers, and cadaver nails obtained from a human tissue bank (Science Care Anatomical, AZ. USA) following approval by the King's College Research Ethics Committee – (study ref no. 04/05-126). Validated ChubTur and TurChub[®] permeation cells were kindly donated by MedPharm Ltd. Ethanol (EtOH) was purchased from BDH Chemicals Ltd (Dorset, UK). Acetonitrile (ACN), Triethylamine, orthophosphoric acid, potassium dihydrogen orthophosphate (KH₂PO₄) and Ringers solution were supplied by Fisher (Leicestershire, UK). Triethylamine, orthophosphoric acid and potassium dihydrogen orthophosphate (KH₂PO₄) were supplied by Fisher (Leicestershire, UK), MedPharm's lysing agent was supplied by MedPharm Ltd., *T.rubrum* was originally isolated from a patient suffering from onychomycosis and was a gift from Cardiff University, sterile gauze filter (Propax, 7.5cm x 7.5 cm 8 ply gauze swab, BP Type 13) was obtained from Smith&Nephew. Adenosine 5-triphosphate standard disodium salt trihydrate substantially vanadium free was obtained from Sigma (Poole, UK). BacTiter-Glo kit and BacTiter Glo substrate were obtained from Promega (Southampton, UK).

TurChub assay

The TurChub[®] assay uses a modified Franz-cell, where sections of human nail serve as the barrier through which the drug initially penetrates through into an agar filled receptor chamber where the dermatophytes (*T.rubrum*) grow. The cells are dosed with the test formulation and then incubated for a set period of time, at a set temperature. After incubation the presence of any zone of inhibition is measured (examples of which are shown in figure 1).

Preparation of human nail clippings (distal)

Initially, distal nail clippings were obtained from volunteers toe nails, which had been grown to a minimum length of 3 mm. All volunteers were required to not have used nail varnish or polish on their toe nails within 6 months and have not shown any signs of disease to their nails within 6 months. All volunteers were asked to remove the distal nail sections using either scissors or standard nail clippers. The nail clippings were then placed into an appropriate container e.g. plastic bag, vial,

envelope etc for transfer to our laboratory. The nail clippings were then placed into an 8 ml bijou bottle per donor/donation and labeled with any details supplied.

Preparation of 3mm x 3mm distal nail segments

Using scissors, the nail clippings were cut into pieces, which were a minimum of 3 mm by 3 mm. The nail clippings were immersed into a 70% ethanol in water solution and vortex mixed for one minute. The ethanol solution was then decanted and replaced with a fresh 70 % ethanol solution and vortex mixed for a further minute. The ethanol solution was then decanted and replaced with Ringer's solution, vortex mixed for one minute and decanted and replaced with fresh Ringer's. This process of washing with Ringer's was carried out a total of three times, replacing the wash solution at each phase. Once the washing process was complete, the nail clippings were placed into a sterile Petri dish without a lid and air dried under a laminar flow cabinet for 30 minutes at room temperature. Once the nail clippings were dry, they were placed into new 8 ml bijou bottles (separate bottle per donor, per batch). Nails were measured for thickness using a sterilized pair of calipers.

Preparation of Standard Sabouraud dextrose agar (SDA)

Briefly, 65 g of the powdered agar was suspended in 1 litre of distilled water. The mixture was then heated to boiling point whilst stirring to dissolve the powdered agar completely. The agar solution was then sterilised in an autoclave for 15 minutes at 121°C.

Preparation of Potato dextrose agar (PDA)

Briefly, 39 g of the powdered agar was suspended in 1 litre of purified water. The mixture was then heated to boiling point whilst stirring to dissolve the powdered agar completely. The agar solution was then sterilised in an autoclave for 15 minutes at 121°C.

Preparation of a suspension of *Trichophyton rubrum*

T. rubrum which was originally isolated from a patient suffering from onychomycosis was sub cultured onto fresh Sabouraud dextrose agar slopes and reference samples were placed into a glycerol solution and cryogenically frozen. Isolates of the dermatophytes were also transferred into Ringer's solution and onto potato dextrose agar and incubated at 28°C for 7 days using the previously tested procedure to produce conidia. The fungal colonies were then covered with 5 ml of Ringer's solution and suspensions made by gently probing the surface with the tip of a Pasteur pipette, generating a mixture of conidial and hyphal fragments. The spore suspension was then filtered through sterile gauze (Smith+Nephew, Propax, 7.5cm x 7.5 cm 8 ply gauze swab, BP Type 13) to remove mycelium. The densities of the suspension was assessed using a UV spectrophotometer at 600 nm, and the Spore suspension adjusted until a spore count of approximately 1×10^7 cfu/ml was achieved by diluting with Ringer's solution. A serial dilution of the final spore suspension and plate count was also carried out for confirmation. The identity of the isolated strain was verified by microscopy and culture on agar.

Preparation of TurChub® cells

The receiver compartment of the TurChub® was filled with a pre-determined calibrated volume of Sabouraud dextrose agar. The agar was then inoculated with 50 µl of previously prepared *T. rubrum* suspension. Nail clippings (approximate size: 3mm x 3mm) were mounted into the validated TurChub® gasket system, to ensure no leakage of formulation around the nail. The gasket system was then mounted into the TurChub® cell ensuring complete contact with the agar in the receiver compartment and clamped in place between the donor and receiver compartments. An initial feasibility study was performed to determine the relative efficacies of Penlac® and Loceryl® when applied to human nail in the TurChub® cells. The nail sections used in this study were cut to a uniform thickness of 5 µm using a microtome. The nail lacquers (0.5 ml) were applied to the apical surface of the nail, the cells occluded with Parafilm® and incubated at 25°C for 7 days.

The main study was performed using full thickness human nails in order to closely mimic the *in vivo* situation in a patient suffering from onychomycosis. In this study the nails were dosed with the novel

dual system penetration enhancers prior to application of the same nail lacquers used in the feasibility study. Penetration enhancer 1 (PE1) was 5% TA (w/w) prepared in 20% EtOH: Water (v/v). Penetration enhancer 2 (PE2) was Urea H₂O₂ solution was prepared in water (Millipore) such that the concentration of the H₂O₂ was 15% (w/v). Cells were dosed with PE1 by applying 0.5 ml to the donor compartment of the ChubTur[®] cell so that the apical surface of the nail was submerged. Following a period of 20 h, the PE1 solution was removed and the donor compartment flooded 3 times with water to wash away any residual PE. Any remaining moisture was removed using a dry tissue. PE2 was then applied in the same way and after 20 h, PE2 was again washed out of the donor chamber and any excess solution was removed using a dry tissue. The relevant nail lacquer was applied (0.5 ml) to the dry clean donor compartment after the application of the PEs. The diffusion cells were then sealed with Parafilm™ to prevent evaporation and incubated for 7 days. A set of control cells in which no penetration enhancer was applied before the nail lacquers were also prepared in the same way.

Infected Nail Model

A second study was performed using a novel infected nail model developed by MedPharm Ltd. In this infected nail model, ATP levels were used as biological marker for antimicrobial activity across human cadaver nails and distal nail clippings. Each nail was stored in an individual bag in a freezer prior to use. Prior to cutting the full cadaver nails into 3 mm x 3 mm segments, the nails were removed from the freezer (leaving them in the individual sealed bags) and placed in a laminar flow cabinet for 30 min to defrost. The cadaver nail was then placed into a sterile universal tube prior to cutting into segments. As the thickness, rigidity and permeability of cadaver nails varies across the entire nail, only the distal section of the cadaver nails was used. The underside of the nail was also irregular, and all loose material was removed where possible, by gently scraping with the scalpel blade. The nails were then sterilised by brief immersion in 70% ethanol, washing in ringers solution and gently heating to 60°C for 15 minutes. A pair of sterile callipers were used to measure the length (in mm) and width (in mm) of the sterile cadaver nail, in order to determine how many 3 x 3 mm sections could be obtained and these were cut using a scalpel. Each nail segment was designated a number to maintain traceability. The thickness of the nail segments were then individually measured using callipers. Distal nail clippings were prepared as detailed above. The underside of the nails were

initially inoculated with *T. Rubrum* (5µl of 1×10^7 cfu/ml) and incubated under controlled temperature and humidity to stimulate growth of the organism on and into the nails. Sacrificial samples were set up to monitor the growth of the organism on the nail samples over the incubation period, and control nails without any organisms were also set up and incubated to ensure no contamination. After establishing the growth of the organisms on the nails, the nails were dosed with one of the test formulations as detailed below. The performance of the formulation was determined after removing the nail sample from the cell and recovering viable microorganisms using a previously validated bioluminescence ATP method.

Dosing regime.

As a result of the data obtained in the TurChub study it was decided the infected nail model would be used to compare the efficacy of both the commercial products (Loceryl® and Penlac®) to a spray product containing terbinafine developed in-house and a range of controls. The terbinafine spray, was formulated by adding terbinafine (1%) to the urea hydrogen peroxide (0.5%) component of the pre-treatment enhancing system, in a co-solvent (15% ethanol) to which a film forming agent (copovidone) was also added prior to addition of hydroflourolkane as the propellant. After the 14 day incubation period one group of infected nails were removed from the incubator and dosed with 1 actuation of Thioglycolic acid spray formulation and returned to the incubator for 8 hours. After this period, the Thioglycolic acid spray formulation was washed off using sterilized water and wiped using a sterile cotton swab. Then 1 actuation of the Urea hydrogen peroxide spray formulation also containing the active (terbinafine), or a placebo formulation containing only Urea hydrogen peroxide, was applied to the nail surface.

A second group of infected nails were dosed with either Penlac® or Loceryl® only (1 µl, this volume was calculated proportionally for the size of the nail clipping based on the directions in the patient information leaflet for application to an infected nail *in vivo*), while a third set were used as an inoculated only control and received no further treatment. Following dosing, all cells were placed back into the incubator for a further 7 days. Three weeks after initial inoculation with *T.rubrum*, all cells were removed from the incubator dismantled and analysed for the presence of ATP. Whereby the nails were aseptically removed from the ChubTur® cells and placed into a 96 well Nunc micro titre plate. The micro titre plate was then placed in the fluorescence plate reader, whereby Bactitre-glo,

containing the lysing agent is added by automated injection at set intervals and the fluorescence measured after a pre-determined period of time to ensure consistency and complete lysis of all viable organism.

ATP assay – calibration

ATP calibration standards of known concentrations (0, 1, 5, 10, 25, 50, 100 and 200 ng/ml) were prepared by diluting the stock ATP standard (1 mg/ml), sequentially, in water. These standards (100 μ l) were then aliquoted into a sterile Nunc 96 well white micro-titre plate followed by the addition of 100 μ l of the MedPharm lysing agent and Promega BacTiter-Glo™ assay reagent. The solution was mixed for a period of 30 sec and the total amount of light that was emitted from the well measured every 10 sec over a total period of 10 min using Biotek FLx800 micro-titre fluorimeter/luminometer. The average of the relative light units measured over the 10 min was then calculated.

Statistical analysis

Statistical analysis of the effect of pre-treatment with the enhancing system on the efficacy (demonstrated by level of ATP activity) of Penlac®, Loceryl® and the terbinafine spray formulation compared to positive and negative controls was evaluated using the Kruskal-Wallis test. A significance level of $P < 0.05$ denoted significance in all cases. In all cases the number of replicates was 5.

RESULTS AND DISCUSSION

TurChub[®] Assay

The initial study was performed using nail samples cut to a uniform thickness of 5 μm using a microtome. In this study a small zone of inhibition was detected following a single application of Penlac[®] ($3.7 \pm 5.7\%$, mean \pm SD) and a larger zone of inhibition following a single application of Loceryl[®] ($93.7 \pm 4.6\%$, mean \pm SD). A secondary study was performed using full thickness human nail sections, in this study no zone of inhibition was detected for either Penlac[®] ($0.00 \pm 0.00\%$) or Loceryl[®] ($0.00 \pm 0.00\%$). Penlac[®] and Loceryl[®] were also applied to the full thickness nail sections following an initial pre-treatment with the permeation enhancing system. Following this pre-treatment a significantly increased zone of inhibition was detected for both commercial formulations (pre-treatment + Penlac[®] $100 \pm 0.00\%$, pre-treatment + Loceryl[®] $46.5 \pm 6.3\%$) through full thickness nail samples. Indeed the pre-treatment followed by application of Penlac[®] resulted in complete kill in all replicates of the sample such that there was no detectable presence of *T. rubrum* in the cell and the samples were identical to the negative control samples that were uninfected ($100 \pm 0.00\%$) (figure 2).

Data from the initial study using 5 μm nail sections indicates that one application of Loceryl[®] alone appears to be a more potent treatment for onychomycosis than Penlac[®] using this model. However in the second part of the study using full thickness nail sections neither Loceryl[®] or Penlac[®] demonstrated any efficacy against *T.rubrum*. This implies that in an *in vivo* situation, where penetration of the full thickness of the nail would be required in order to guarantee complete cure, both Penlac[®] and Loceryl[®] would perform poorly. However, this may be an unfair comparison as each lacquer was only applied once in this study as opposed to the repeated applications (Loceryl[®] 1-2 times per week until the nail has grown out and Penlac[®] daily until the nail has grown out) indicated in their use for the treatment of onychomycosis. Also patient instructions for the use of both Loceryl[®] and Penlac[®] involve debridement and cleaning of the nail prior to application of the lacquer, a process that was not followed in this study. Nevertheless, historical data supports these findings with incidences of successful treatment very low, and relapse rates high, despite the extremely long treatment times involved. In addition, the relative effectiveness of the two marketed formulations *in vivo* seems to be depicted in the TurChub[™] *in vitro* model.

The purpose for deviating from the standard directions for use was given in the patient information leaflet for Penlac[®] and Loceryl[®] was to demonstrate the ability of the penetration enhancing system to alter the barrier properties of the nail after only a single application. Data from the present study confirms the ability of a thioglycolic acid/ hydrogen peroxide pre-treatment to significantly enhance the effectiveness of both Penlac[®] and Loceryl[®] across full thickness nail *in vitro*; even after only one application. A greater improvement in the efficacy of Penlac[®] compared to Loceryl[®] was seen in the presence of the penetration enhancer and there are at least two possible explanations for this. The most likely is due to the fact that Ciclopirox (Penlac[®]) has a lower molecular weight than amorolfine (Loceryl[®]) and as such has a greater inherent permeability making the effect of the enhancement more apparent. An alternative possibility is that the pre-treatment is helping to maintain ciclopirox in solution on the surface of the nail and thus sustaining drug absorption resulting in greater efficacy. Such results suggest that any potential formulation should be developed and optimised for the drug selected. The increased rate of unguis permeation observed for both ciclopirox and amorolfine in the presence of the permeation enhancing system could lead to a significant decrease in required treatment time and combined with an increase in patient compliance result in an increase in overall successful treatment outcomes.

Infected nail model

The infected nail model was used to compare Penlac[®] and Loceryl[®] to a spray product containing terbinafine developed in-house and a range of controls. The terbinafine spray formulation was significantly better than Penlac[®] and Loceryl[®] at a 95% confidence level ($p < 0.05$) using infected cadaver nails. The terbinafine spray formulation (incorporating the enhancers) gave complete kill in all repeats of the sample, and levels of ATP recovered from the nails ($5.4 \pm 3.2\%$ (mean \pm SD) of infected control levels) were equivalent to negative control whereby no organisms were added to the nail ($5.3 \pm 1.6\%$ of infected control levels). In comparison the spray vehicle (i.e. a placebo containing no terbinafine), Penlac[®] and Loceryl[®] all showed no statistically significant decrease ($p > 0.05$) in ATP levels recovered from the nails, compared to infected controls which received no treatment (figure 3) ($78.9 \pm 32.8\%$, $87.4 \pm 23.1\%$ and $79.0 \pm 32.8\%$ of infected control levels respectively). When the healthy volunteer distal nail sections were used Penlac[®] ($31.9 \pm 1.7\%$) and Loceryl[®] ($24.0 \pm 0.7\%$) both formulations showed a statistically significant decrease ($p < 0.05$) in percentage ATP levels

compared to the infected control (100%) but the levels did not decrease to those seen in the negative untreated control ($1.93 \pm 1.37\%$).

It is thought that the thioglycolic acid component of the pre-treatment system causes reduction of –S-S- bonds in the keratin to –SH where the addition of hydrogen results in the cleavage of the disulphide bridge which in turn leads to the formation of cysteine amino acid molecules, as is known to happen in hair care products [36]. In hair care products it is well known that application of urea hydrogen peroxide results in the re-formation of the broken disulphide bridges [37], however in the nail previously reported data has shown that application of urea hydrogen peroxide following initial administration of thioglycolic acid actually causes a further increase in the permeability of the nail [35] thus suggesting that in the case of the nail the –S-S- bonds are not reformed in the same way as in the hair. One possible explanation for this phenomena is that as a result of the fairly high concentration and prolonged application (20h) of the thioglycolic acid, disulphide bonds do not reform because the initial cleavage of the bridges is damaging to the nail keratin structure resulting in a semi-permanent (longer than 20h) reduction in the integrity of the nail barrier and therefore increased drug permeation.

Although combination of the permeation enhancing system with all three active agents investigated resulted in increased permeation of all three agents and increased the apparent efficacy of each, as demonstrated by the infected nail model, the best results were observed when using terbinafine as the active agent. As such the increased effectiveness of terbinafine may not only be as a result of its enhanced unguinal absorption but also because of its increased potency (minimum inhibitory concentration (MIC) ($0.016 - 0.125 \mu\text{g/ml}$)) compared to ciclopirox and amorolfine (MICs of $0.25-2 \mu\text{g/ml}$ and $0.04 - 0.063 \mu\text{g/ml}$ respectively)

CONCLUSION

The nail is a very difficult barrier to overcome when attempting to delivery drugs to the underside of the nail or the nail bed [3, 21, 38]. This is reflected in the low success rates and high relapse rates of the products currently available for the topical treatment of onychomycosis [11, 12]. This study has clearly demonstrated that the use of a novel permeation enhancing system which fundamentally alters

the chemical structure so that the rate of permeation of a range of antifungal agents is significantly increased. This proof of concept study involved the sacrificial termination of all samples at the end of the study and further work is required to understand the nature of the changes occurring in the nail structure and the length of duration of the effect. As demonstrated in this study this penetration enhancing system could potential be combined with the current topical treatments for onychomycosis, Penlac[®] and Loceryl[®], to create a single treatment with enhanced permeation of their antifungal agents (ciclopirox and amorolofine respectively). As shown in this study a permeation enhancing system could also potentially be formulated into a nail lacquer or spray formulation containing terbinafine. Terbinafine is the current gold standard oral treatment for onychomycosis, but has significant systemic side effects which limit its use in this indication, if terbinafine could be delivered topically in this way it would significantly reduce the chances of systemic toxicity.

ACKNOWLEDGEMENTS AND FUNDING

The authors would like to thank MedPharm for supporting this study

CONFLICT OF INTEREST

This work was funded by MedPharm Ltd who have submitted a patent application for the work described within. Three of the authors are direct employees of MedPharm Ltd, the remaining authors have collaborated with MedPharm on this and other previous and ongoing research projects.

References

1. Williams, H.C., *The epidemiology of onychomycosis in Britain*. British Journal of Dermatology, 1993. **129**(2): p. 101-9.
2. Editorial, *Prevalence, morbidity, and cost of dermatological diseases*. Journal of Investigative Dermatology, 1979. **73**(5 Pt 2): p. 395-401.
3. Elewski, B.E., *Onychomycosis: pathogenesis, diagnosis, and management*. Clinical Microbiology Reviews, 1998. **11**(3): p. 415-29.
4. Ginter, G., et al., *[Increasing frequency of onychomycoses--is there a change in the spectrum of infectious agents?]*. Mycoses, 1996. **39 Suppl 1**: p. 118-22.
5. Goodfield, M.J.D., L. Andrew, and E.G.V. Evans, *Short term treatment of dermatophyte onychomycosis with terbinafine*. BMJ, 1992. **304**: p. 1151-1154.
6. Heikkila, H. and S. Stubb, *The prevalence of onychomycosis in Finland*. British Journal of Dermatology, 1995. **133**(5): p. 699-703.
7. Roberts, D.T., *Prevalence of dermatophyte onychomycosis in the United Kingdom: results of an omnibus survey*. British Journal of Dermatology, 1992. **126 Suppl 39**: p. 23-7.
8. Sais, G., A. Jucgla, and J. Peyri, *Prevalence of dermatophyte onychomycosis in Spain: a cross-sectional study*. British Journal of Dermatology, 1995. **132**(5): p. 758-61.
9. Repka, M.A., et al., *Nail morphology studies as assessments for onychomycosis treatment modalities*. International Journal of Pharmaceutics, 2002. **245**(1-2): p. 25-36.
10. Kobayashi, Y., et al., *Drug permeation through the three layers of the human nail plate*. Journal of Pharmacy & Pharmacology, 1999. **51**(3): p. 271-8.
11. Blank, H., et al., *The treatment of dermatomycoses with orally administered griseofulvin*. A M A Archives of Dermatology, 1959. **79**(3): p. 259-66.
12. Van der Schroeff, J.G., et al., *A randomized treatment duration-finding study of terbinafine in onychomycosis*. British Journal of Dermatology, 1992. **126**(Supplement): p. 36-39.
13. Ajit, C., et al., *Terbinafine-Associated Hepatototoxicity*. Am J Med Sci, 2003. **325**: p. 292-295.
14. Goodfield, M.J.D., et al., *Treatment of dermatophyte infection of the finger- and toenails with terbinafine (SF 86-327, Lamisil), an orally active fungicidal agent*. British Journal of Dermatology, 1989. **121**: p. 753-757.
15. Chambers, W.M., et al., *Terbinafine-induced hepatic dysfunction*. European Journal of Gastroenterology & Hepatology, 2001. **13**(9): p. 1115-8.
16. Bohn, M., et al., *The dermatopharmacologic profile of ciclopirox 8% nail lacquer*. Journal of the American Podiatric Medical Association, 2000. **90**(10): p. 491-4.
17. Bohn, M., et al., *Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis*. Journal of the American Academy of Dermatology, 2000. **43**(4 Suppl): p. S57-69.
18. Gupta, A.K., et al., *Ciclopirox nail lacquer solution 8% in the 21st century*. Journal of the American Academy of Dermatology, 2000. **43**(4 Suppl): p. S96-102.
19. Gupta, A.K., et al., *Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis.[see comment]*. Journal of the American Academy of Dermatology, 2000. **43**(4 Suppl): p. S70-80.
20. Gupta, A.K. and A.K. Gupta, *Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States*. Journal of the American Academy of Dermatology, 2000. **43**(4 Suppl): p. S81-95.

21. Seebacher, C., *Action mechanisms of modern antifungal agents and resulting problems in the management of onychomycosis*. Mycoses, 2003. **46**(11-12): p. 506-10.
22. Akomeah, F.K., et al., *Variability in human skin permeability in vitro: comparing penetrants with different physicochemical properties*. Journal of Pharmaceutical Sciences, 2007. **96**(4): p. 824-34.
23. Barry, B.W., *Novel mechanisms and devices to enable successful transdermal drug delivery*. European Journal of Pharmaceutical Sciences, 2001(14): p. 101-114.
24. Bos, J.D., et al., *The 500 Dalton rule for the skin penetration of chemical compounds and drugs*. Experimental Dermatology, 2000. **9**(3): p. 165-9.
25. Brown, M.B., et al., *Dermal and transdermal drug delivery systems: current and future prospects*. Drug Delivery, 2006. **13**(3): p. 175-87.
26. Brown, M.B., et al., *Transdermal drug delivery systems: skin perturbation devices*. Methods in Molecular Biology, 2008. **437**: p. 119-39.
27. Hadgraft, J., *Skin, the final frontier*. International Journal of Pharmaceutics., 2001. **224**(1-2): p. 1-18.
28. Kezic, S., *Human in vivo studies of dermal penetration, their relation to in vitro prediction*. Perspectives in Percutaneous Penetration, 2004. **9a**.
29. Scott, R.C. and P.H. Dugard, *The properties of skin as a diffusion barrier and route for absorption*, in *Pharmacology of the skin I*, Greaves M.W. and Schuster S., Editors. 1989, Springer-Verlag,: Berlin. p. 93-114.
30. Wessel, S., et al., *Hydration of human nails investigated by NIR-FT-Raman spectroscopy*. Biochimica et Biophysica Acta, 1999. **1433**(1-2): p. 210-6.
31. Monti, D., et al., *In vitro transungual permeation of ciclopirox from a hydroxypropyl chitosan-based, water-soluble nail lacquer*. Drug Development & Industrial Pharmacy, 2005. **31**(1): p. 11-7.
32. Malhotra, G.G., et al., *Investigation of nail permeation enhancement by chemical modification using water as a probe*. Journal of Pharmaceutical Sciences, 2002. **91**(2): p. 312-23.
33. Murdan, S. and S. Murdan, *Enhancing the nail permeability of topically applied drugs*. Expert Opinion on Drug Delivery, 2008. **5**(11): p. 1267-82.
34. Khengar, R.H., et al., *Nail swelling as a pre-formulation screen for the selection and optimisation of unguinal penetration enhancers*. Pharmaceutical Research, 2007. **24**(12): p. 2207-12.
35. Brown, M.B., et al., *Overcoming the nail barrier: A systematic investigation of unguinal chemical penetration enhancement*. International Journal of Pharmaceutics, 2009. **370**(1-2): p. 61-7.
36. Bolduc, C. and J. Shapiro, *Hair care products: waving, straightening, conditioning, and coloring*. Clinics in Dermatology, 2001. **19**(4): p. 431-6.
37. Wickett, R.R., *Permanent waving and straightening of hair*. Cutis, 1987. **39**(6): p. 496-7.
38. Einarson, T.R., et al., *Clinical and economic factors in the treatment of onychomycosis*. Pharmacoeconomics, 1996. **9**(4): p. 307-20.

FIGURE LEGENDS

Figure 1. Four examples of typical zone of inhibition results observed in the TurChub® cell test system


Figure 2: Comparison of zones of inhibition observed in the TurChub cell test system following application of the test systems to the nail surface (Figures are calculated as a percentage of the maximum possible zone of inhibition, Mean \pm SEM, n = 6).

Figure 3. Comparison of % ATP recovered compared to infected control (Mean \pm SEM, n=5 with exception of '**' where n=4, cell rejected after failing inter QC) following a single 1 μ l dose at t=0 and incubated for 7 days treatment



Approximately 2 cm zone of inhibition (indicated by white arrow)

No zone of inhibition



Total kill

Very small zone of inhibition e.g. 3 mm

